27576906|t|Inactivation of Cancer Mutations Utilizing CRISPR/Cas9
27576906|a|Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.
27576906	0	12	Inactivation	T169	C0544461
27576906	16	32	Cancer Mutations	T049	C1516197
27576906	43	54	CRISPR/Cas9	T044	C3658355
27576906	64	87	whole-genome sequencing	T063	C3640076
27576906	120	129	mutations	T045	C0026882
27576906	141	154	tumorigenesis	T191	C0596263
27576906	156	166	functional	T169	C0205245
27576906	189	198	mutations	T045	C0026882
27576906	247	262	test functional	T169	C0205245
27576906	263	272	relevance	T080	C2347946
27576906	276	291	tumor mutations	T049	C1516197
27576906	302	313	CRISPR/Cas9	T044	C3658355
27576906	325	338	comprehensive	T080	C1880156
27576906	339	344	sgRNA	T114,T123	C0082774
27576906	378	383	assay	T059	C1510438
27576906	420	426	sgRNAs	T114,T123	C0082774
27576906	455	462	dissect	T169	C0205239
27576906	472	488	cancer mutations	T049	C1516197
27576906	494	503	potential	T080	C3245505
27576906	504	517	applicability	T080	C1706839
27576906	521	542	personalized medicine	T061	C2718059
27576906	554	569	therapeutic use	T080	C0039795